New eye drops aim to soothe dry eye in bone marrow transplant patients

NCT ID NCT03414645

Completed Symptom relief Sponsor: Cambium Bio Limited Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether CAM-101 eye drops are safe and can help relieve dry eye in people who developed the condition after a bone marrow transplant (graft-versus-host disease). 64 adults received either a low or high dose of CAM-101 or a placebo drop four times a day for six weeks. The main focus was on safety, but researchers also looked for signs of symptom improvement.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CAM-101 (fibrinogen-depleted human platelet lysate) eye drops
What this could lead to: If successful, this could lead to a new treatment option for dry eye in people with graft-versus-host disease, easing discomfort and improving eye health.
What could go wrong: This is an early-phase trial with only 64 participants, so results may not apply to everyone. The main goal is safety, not proof of effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRY EYE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dry eye syndrome graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRY EYE GRAFT-VERSUS-HOST DISEASE OCULAR DISCOMFORT

Contacts and locations

Locations

Byers Eye Institute of Stanford University

Palo Alto, California, 94303, United States
Duke University Eye Center

Durham, North Carolina, 27710, United States
Massachusetts Eye and Ear Infirmary

Boston, Massachusetts, 02114, United States
Oregon Health Sciences University - Casey Eye Institute

Portland, Oregon, 97239, United States
University of Michigan - Kellogg Clinical Research Center

Ann Arbor, Michigan, 48105, United States
University of Minnesota

Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.